Brazil Drug Pricing Reform Adds 6 Nations, Eases Price Caps

Health

For the first time in years, Brazil drug pricing is getting a rewrite. A new rulebook from the country’s medicine-price regulator, in force from late April, changes how the ceiling on almost every drug is set.

Unlike the United States, Brazil does not let the market set the price of medicines. A regulator decides the most a company can charge for each drug.

That regulator has just rewritten its rulebook for the first time in years, and the changes take effect on 29 April 2026.

How Brazil Drug Pricing Works

The body in charge is CMED, the Chamber for the Regulation of the Medicine Market. It sets a ceiling price for every medicine sold in the country.

One of its main tools is “external reference pricing” — comparing what other countries pay for a drug and capping the Brazilian price accordingly.

Nearly every prescription and over-the-counter medicine sold in Brazil is affected, from cheap generics to costly cancer drugs.

Price control is a core feature of Brazil’s health policy, meant to keep essential medicines affordable in a middle-income country with deep inequalities.

But the system, patched rather than overhauled for years, had drawn complaints that it was rigid, opaque and poorly suited to newer kinds of medicine.

What the New Rule Changes

The overhaul, Resolution No. 3/2025, was published at the end of December 2025 and enters into force on 29 April 2026, after a 120-day transition.

Its headline change is the reference list. Brazil will now compare prices against 14 countries instead of nine, adding Germany, Japan, the United Kingdom, Norway, Mexico and South Africa, and removing New Zealand.

It also expands the categories used to classify drugs from six to eight — a technical shift meant to capture products, such as biologics and combination therapies, that the old boxes handled poorly.

In practice, the reference basket acts as a global price anchor: if a drug is cheaper in the comparison countries, Brazil pushes its own ceiling down toward that level.

The reform follows about two years of debate, after repeated complaints from industry, regulators and health economists alike.

A Nudge Toward Innovation

Perhaps the most consequential change concerns “incremental innovation.” Until now, a tweaked version of an existing drug — a new dose, form or combination — was largely capped at the price of the original.

Under the new rule, such products can instead be priced against what the medicine costs abroad, potentially allowing higher prices.

Regulators frame this as rewarding genuine improvement. Critics will watch whether it simply lets companies charge more for minor changes.

The distinction matters for a wave of reformulated and combination drugs that blur the line between genuine breakthroughs and modest updates.

The 2026 Price Caps

Separately from the structural reform, CMED set the ceiling on annual price rises for 2026.

Companies may raise prices by up to 3.81%, 2.47% or 1.13%, depending on how competitive each drug’s market is; the most competitive segments get the smallest increases.

Such caps are routine — CMED sets them every year — but they are what most Brazilians actually feel at the pharmacy counter.

The bands are tied to how much competition each medicine faces — an attempt to let market forces, not just the regulator, hold prices down where rivals exist.

Who Wins and Who Worries

The pharmaceutical industry has broadly welcomed the modernisation, arguing the old system discouraged bringing new treatments to Brazil.

Patient and consumer groups will watch prices closely, wary that more pricing “flexibility” can shade into higher costs in a country where many pay for medicines out of pocket.

Brazil’s public health system, the SUS, which buys drugs in vast quantities, has its own stake: the rules that cap private prices also shape what the state pays.

Any change that raises what patients pay is politically sensitive in Brazil, where the cost of medicine is a perennial complaint and an election-year issue.

What Foreigners Should Know

For international drugmakers, the reform matters because Brazil is one of the world’s largest medicine markets, and its pricing rules decide whether launching there is worthwhile.

Adding Germany, Japan and the UK to the benchmark basket ties Brazilian prices more closely to wealthy markets, which can cut both ways for consumers.

The real test comes after 29 April, when the first prices are set under the new system and the winners and losers become visible.

It also signals how open Brazil wants to be to advanced treatments, many of them expensive and slow to reach price-controlled markets.

More: South Africa news in English, every day from The Rio Times.

Frequently Asked Questions

What is CMED?

CMED, the Chamber for the Regulation of the Medicine Market, is the Brazilian body that sets the maximum prices companies can charge for medicines, using comparisons with other countries and annual caps.

When do Brazil’s new drug pricing rules take effect?

Resolution No. 3/2025 was published in late December 2025 and enters into force on 29 April 2026, after a 120-day transition period.

What changes for medicine prices in Brazil?

The reform expands the reference countries from 9 to 14, increases pricing categories from six to eight, and lets incremental innovations be priced against foreign prices rather than capped at a predecessor. Separately, 2026 annual increases are capped at up to 3.81%.

Sources: CMED; Resolution No. 3/2025.

This article was drafted with automated assistance and reviewed before publication. How we use AI · Report an error